DPTX3186, a first-in-class beta-catenin condensate modulator, received Orphan Drug Designation and Fast Track Designation from FDAClinical entry validates condensate modulator…
February 04, 2026 09:35 ET | Source: Adial Pharmaceuticals, Inc GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial…
Initiation of trial marks first-in-human milestone for Neomorph’s novel molecular glue degrader platform February 03, 2026 13:08 ET | Source:…
Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale from baseline of +0.64 points, compared to natural…
First in class study of an investigational ACTH receptor antagonist aims to address significant unmet need in children and adolescents…
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia and…
Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PT…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued…
January 04, 2026 16:00 ET | Source: Crinetics Pharmaceuticals, Inc. SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals,…
The secondary analysis of the PACE trial highlights the value of counting Circulating Tumor Cells (CTCs) in the blood to…